SEARCH

SEARCH BY CITATION

References

  • 1
    Iturriza-Gómara M, Kang G, Gray J. Rotavirus genotyping. Keeping up with an evolving population of human rotaviruses. J Clin Virol 2004; 31: 25965.
  • 2
    Rennels MB, Glass RI, Dennehy PH et al. Safety and efficacy of high-dose rhesus–human reassortant rotavirus vaccines – report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97: 713.
  • 3
    Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 1122.
  • 4
    Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 2333.
  • 5
    Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception – United States, 1999. MMWR Recomm Rep 2004; 53: 7869.
  • 6
    Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27: 593641.
  • 7
    Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 60614.
  • 8
    Zaman K, Anh DD, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 61523.
  • 9
    Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 28998.
  • 10
    Iturriza-Gómara M, Dallman T, Bányai K et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011; 139: 895909.
  • 11
    Curns AT, Panozzo CA, Tate JE et al. Remarkable postvacination spatiotemperal changes in United States rotavirus activity. Pediatr Infect Dis J 2011; 30: S545.
  • 12
    Buttery JP, Lambert SB, Grimwood K, Lambert SB. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s national childhood vaccine schedule. Pediatr Infect Dis J 2011; 30: S259.
  • 13
    Field EJ, Vally H, Grimwood K et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126: e50612.
  • 14
    Lambert SB, Faux CE, Hall L et al.. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Australia 2009; 191: 15760.
  • 15
    Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011; 30: S214.
  • 16
    Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis 2011; 15: e20610.
  • 17
    Ikedo do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLOS Medicine 2011; 8: 111.
  • 18
    Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalisations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011; 127: e915.
  • 19
    Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, TotaTeq®in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010; 169: 137986.
  • 20
    Richardson V, Hernandez-Pichardo  , Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010; 362: 299305.
  • 21
    Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 2011; 30: S115.
  • 22
    Molto Y, Cortes JE, De Oliveira LH et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis J 2011; 30: S1620.
  • 23
    Tate JE, Cortese MM, Payne DC et al. Uptake, impact and effectiveness of rotavirus vaccination in the United States. Pediatr Infect Dis J 2011; 30: S5660.
  • 24
    Wang FT, Mast TC, Glass RJ et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125: e20813.
  • 25
    Tate JE, Mutuc JD, Panozzo CA et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30: S304.
  • 26
    Bégué RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010; 126: e405.
  • 27
    Boom JA, Tate JE, Sahni LC et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010; 29: 11335.